<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <title>MyProject</title>
    <link rel="stylesheet" href="bundle.min.css">
    <script src="js/jquery.min.js"></script>
   <script src="js/script.js"></script>
</head>
<body>
<section class="mainBox">
<header>
        <div class="topHeader">
            <div class="logo">
                  <img src="images/BRIV_LOGO_mobile.jpg" alt="Logo image"
                  srcset="images/BRIV_LOGO_mobile.jpg 400w, images/BRIV_Logo_391x114_-_IN_BUILD_KIT.png 750w"
                  sizes="(min-width: 1024px) 35vw,
                  (min-width: 640px) and (max-width: 1023px) 50vw,
                  (max-width: 639px) 100vw">  
            </div>
            <div class="text">
               <p> Important Safety Information | Prescribing Information | For Patient</p>
               <img src="images/ucbCARES®_1-844-599-CARE_(2273).png" alt="ucb">
            </div>
        </div>
        <div class="hamburger-container">
            <ul class="hamburger">
              <li></li>
              <li></li>
              <li></li>
            </ul>
        </div>
        <nav>     
           <ul class="navMenu">
               <li><a href="#">OVERVIEW</a></li>
               <li><a href="#">MOA</a></li>
               <li> <a href="#">PK PROFILE</a></li>
               <li><a href="#">ADMINISTRATION</a></li>
               <li><a href="#">ADULT EFFICACY</a></li>
               <li><a href="#">SAFETY AND TOLERABILITY</a></li>
               <li><a href="#">HOSPITAL DISCHARGE</a></li>
           </ul>
        </nav>
   
</header>

<main>
   
        <div class="block1">
            <div class="triangle">
                <img src="images/H.1_Left_Chevron_Graphic_174x445_-_IN_BUILD_KIT.png">
            </div>
            <div class="txtHeaders">
            <div class="headerText first">BRIVIACT® (BRIVARACETAM) CV INJECTION FOR ADULT <br>
                PARTIAL-ONSET SEIZURE PATIENTS IN THE HOSPITAL
            </div>
  
               <hr>
            <div class="headerText second">BECAUSE IN NEUROCRITICAL CARE, THERE IS LIMITED TIME <br>
                FOR COMPLICATED ADMINISTRATION
            </div>
            </div>
        </div>
        <div class="slice"><img src="images/Slice_4.png" alt="slice" width="100%"></div>

        <div class="molecularBlock">
            <h2>BRIVIACT is a molecular entity in the racetam class that targets SV2A</h2>
            <div class="list">
            <ul>
                <li>
                    The presize mechanizm by which BRIVIACT exerts its anticonvulsant activity in unknown<sup>1</sup>
                </li>
                <li>
                    BRIVIACT is the rezult of a large rationaldiscovery effort in which USB screened-12,000 compounds in an effort to find another synaptic vesicle protein(SV2A) ligand as a new addition to the racetam class<sup>3</sup>
                </li>
                <li>
                    BRIVIACT displays a high and selective afinity for SV2A in the brain, which main contribute to the anticonvulsant effect<sup>1</sup>
                </li>
            </ul>
            </div>
            <p class="subtitle">SV2A BINDING IS PROPOSED TO BE THE PRIMARY MECHANISM OF ACTION (MOA) FOR BRIVIANT<sup>4-6</sup></p>
            <div class="imgBlock">
                <div class="image">
                    <figure>
                        <img src="images/Slice.png" alt="molecula" width="100%">
                    </figure>
                    <p class="additionalImg"><sup>*</sup>The precise mechanizm by which levetiracetam exerts its anticonvulsantactivity is unknown. Not all proposed machanizm of levetiracetam are depicted. <br/>
                        <sup>*</sup>High-voltage-activated calcium channel.</p>
                 
                </div>
               <div class="list">
                   <ul>
                       <li>
                           Depiction of proposed MOA based on <i>in vitro</i> studies
                       </li>
                       <li>
                           BRIVIACT displays 15-30x higherbaffinity for SV2A than levetiracetam<sup>4</sup>
                       </li>
                       <li>
                           <b>Implications for efficacy and satefy are not known</b>
                       </li>
                   </ul>
                   <p class="additionalList">Levetiracetam is a product manufactured by USB.</p>
               </div>

            </div>
        </div> 
        <div class="slice2"><img src="images/Slice_shape.png" alt="slice"></div>
        <div class="briviactExibits">
             <h2>BRIVIACT exibits a linear and time-independent pharmacokinetic profile<sup>1</sup></h2>
             <table>
                <caption>BRIVIACT</caption>
                     <tr>
                         <th rowspan="2">Absorption</th>
                         <td>
                             Median T <sub>max</sub>
                             <ul>
                                 <li>Following IV 2-minute bolus administered: &lt;5-minute<sup>2</sup></5-minute>
                                    <ul>
                                        <li>Plasma consentrations are simils with IV infusion administration<sup>7</sup></li>
                                    </ul>
                                </li>
                                 <li>
                                     Following oral administration without food: 1hour<sup>1</sup>
                                 </li>
                                 <li>1.04</li>
                             </ul>
                         </td>
                     </tr>
                     <tr>
                         <td><sup>1</sup>Lipophilicity is a key attribute of drug brain permeability and was measured <i>in vito</i>at pH 7.4(partition in water and octane).<sup>5</sup></td>
                     </tr>
                     <tr>
                         <th>Distribution</th>
                         <td>
                             <ul>
                                 <li>
                                     Rapidly and evenly distributed in most tissues<sup>1</sup>
                                 </li>
                                 <li>
                                     Weakly bound to plasma proteins (&gt;20%)<sup>1</sup>
                                 </li>
                                 <li>
                                     Steady state is reached after -2 days<sup>6</sup>
                                 </li>
                             </ul>
                         </td>
                     </tr>
                     
                     <tr>
                         <th>Metabolism</th>
                         <td>
                             <ul>
                                 <li>Primarily mediated by amidase hidrolysis<sup>1</sup></li>
                                 <li>Secondarily mediated by CYP2C19 hydrohylation and CYP2C9 hydrolysis<sup>1</sup></li>
                                 <li>Dose adjustment is recommended for patients with end-stage renal disease undergoing dialysis because there are no data in these patients<sup>1</sup></li>
                             </ul>
                         </td>
                     </tr>
                     <tr></tr>
                
             </table>
        
            </div>

        <div class="slice2"><img src="images/Slice_shape.png" alt="slice"></div>
        <div class="block2">
            <article class="firstArticle">
                <h2>Adult efficacy was established in pivotal trials</h2>
                <p class="subtitle">Pivotal trial program design and results<sup>1</sup></p>
                <div class="mainSectionBlock">
                    <div class="trialDesign">
                        <ul>Trial design 
                            <li>Effectiveness was established in 3 fixed-dose, randomized, double-blind, placebo-controlled, multicenter studies, which included 1550 adult patients<sup>1</sup> 
                            <li>Enrolled adult patients had partial-onset seizures that were not adequately controlled by 1 to 2 concomitant antiepileptic drugs (AEDs)<sup>1</sup>
                            <li>Adult patients taking concomitant levetiracetam were excluded from Study 3<sup>1</sup>
                        </ul>            
                    </div>
                    <div class="trialResult">
                        <ul>Trial results 
                            <li>25.2% and 25.7% reduction over placebo with BRIVIACT 100 mg/day (n=252) and 200 mg/day (n=249) respectively in partial-onset seizure frequency adjusted to 28 days during the treatment period in Study 3, when added to current therapy<sup>1</sup></li> 
                            <li>≥50% response achieved by 30.0%, 38.1%, and 37.8% of patients with BRIVIACT 50 mg/day, 100 mg/day, and 200 mg/day vs. 20.2% with placebo in pooled results from all three studies<sup>8</sup></li>
                       </ul>
                     </div>
                    <div class="briviant">
                        <p class="subtitle">BRIVIACT was efficacious in patients who had prior levetiracetam EXPOSURE</p>
                            <ul> In Study 3, approximately 54% of adult patients had prior exposure to levetiracetam and were evaluated in a pre-specified analysis. Adult patients taking concomitant levetiracetam were excluded from the study.<sup>1</sup> 
                                <li>18.2% and 21.3% reduction over placebo with BRIVIACT 100 mg/day and 200 mg/day, respectively, in partial-onset seizure frequency adjusted to 28 days during the treatment period in Study 3 in patients with prior levetiracetam exposure<sup>8</sup></li>
                                    <br>     
                                    <figure>
                                        <figcaption>Reasons for discontinuing levetiracetam prior to inclusion in Study 3<sup>8</sup>:</figcaption>
                                             <img src="images/Vector_Smart_Object.png" alt="percents" width="100%">
                                     </figure>  
                                <li>BRIVIACT studies showed no additional benefit when co-administered with levetiracetam<sup>1</sup></li>
                           </ul>
                    </div>
                </div>
            </article>

        </div>

       

    
</main>

<footer>
    <div class="footerBlockFirst">
        <h4>Contact information</h4>
        <div class="footerBlock1">If you have any questions or want more information, please contact ucbCARES® at 1-844-599-CARE (2273) or ucbCARES@UCB.com. We're here to help.</div>
        <div class="footerBlock2">Important Safety Information  |  Prescribing Information  |  Privacy Policy  |  Terms of Use  |  Contact Us</div>
    </div>  
    <div class="footerBlockSecond">
        <div class="footerBlock3">BRIVIACT® and ucbCARES® are registered trademarks of the UCB Group of Companies.
            All other trademarks are the property of their respective holders.
            ©2020 UCB, Inc., Smyrna, GA 30080. All rights reserved.
            US-P-BR-EPOS-2000022 </div>
        <div class="footerBlock4">
            <img src="images/ucb_1c_wht_w_tag.png" alt="footerLogo">
           <p> UCB Inc., 1950 Lake Park Driv <br> Smyrna, GA 30080</p>
        </div>
    </div>
   
</footer>
</section>

</body>
</html>